Linzagolix
CAS No. 935283-04-8
Linzagolix( —— )
Catalog No. M27897 CAS No. 935283-04-8
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 89 | In Stock |
|
| 5MG | 80 | In Stock |
|
| 10MG | 123 | In Stock |
|
| 25MG | 269 | In Stock |
|
| 50MG | 431 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLinzagolix
-
NoteResearch use only, not for human use.
-
Brief DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis.
-
DescriptionLinzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibacterial
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number935283-04-8
-
Formula Weight508.42
-
Molecular FormulaC22H15F3N2O7S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (245.86 mM)
-
SMILESCOc1cc(F)c(cc1OCc1c(OC)ccc(F)c1F)-n1c(=O)[nH]c2csc(C(O)=O)c2c1=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
2'-Deoxyguanosine mo...
Deoxyguanosine is a nucleoside consisting of the base guanine and the sugar deoxyribose. It is like guanosine but with one oxygen atom removed. It is a nucleoside component of DNA. Deoxyguanosine can be converted to 8-hydroxy-deoxyguanosine (8-OHdG) due to hydroxyl radical attack at the C8 of guanine.
-
Epaminurad HCl
Epaminurad HCl is a URAT1 inhibitor with partial inhibition of OAT1 and OAT3 (organic anion transporters).Epaminurad HCl is a pro-uric acid excretory agent used for the prevention and treatment of gout and hyperuricemia.
-
NTRC 0066-0
NTRC 0066-0 is an orally available, selective and potent inhibitor of threonine tyrosine kinase (TTK) that inhibits phosphorylation of TTK substrates and induces chromosome missegregation in cell lines and mice for cancer research.
Cart
sales@molnova.com